Published in Infect Immun on January 01, 2003
Identification and molecular characterization of EatA, an autotransporter protein of enterotoxigenic Escherichia coli. Infect Immun (2004) 1.45
Importance of heat-labile enterotoxin in colonization of the adult mouse small intestine by human enterotoxigenic Escherichia coli strains. Infect Immun (2006) 1.43
Associations between mucosal innate and adaptive immune responses and resolution of diarrheal pathogen infections. Infect Immun (2009) 0.98
The molecular basis for control of ETEC enterotoxin expression in response to environment and host. PLoS Pathog (2015) 0.85
Maternal Vaccination with a Fimbrial Tip Adhesin and Passive Protection of Neonatal Mice against Lethal Human Enterotoxigenic Escherichia coli Challenge. Infect Immun (2015) 0.80
Capture efficiency of Escherichia coli in fimbriae-mediated immunoimmobilization. Langmuir (2011) 0.77
Immunogenicity of a fusion protein comprising coli surface antigen 3 and labile B subunit of enterotoxigenic Escherichia coli. Iran Biomed J (2014) 0.75
Plasmid-controlled colonization factor associated with virulence in Esherichia coli enterotoxigenic for humans. Infect Immun (1975) 14.65
Pathogenesis of Escherichia coli diarrhea. N Engl J Med (1971) 10.36
Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J Bacteriol (1983) 8.19
Suckling mouse model for detection of heat-stable Escherichia coli enterotoxin: characteristics of the model. Infect Immun (1976) 5.86
Determination of total protein. Methods Enzymol (1983) 5.62
Subclass restriction of murine anti-carbohydrate antibodies. J Immunol (1978) 4.99
Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol (1996) 4.47
Simple adult rabbit model for Vibrio cholerae and enterotoxigenic Escherichia coli diarrhea. Infect Immun (1981) 3.69
Immunization of suckling pigs against enteric enterotoxigenic Escherichia coli infection by vaccinating dams with purified pili. Infect Immun (1978) 2.94
An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol Methods (1986) 2.50
Immunity to enterotoxigenic Escherichia coli. Infect Immun (1979) 2.30
Interleukin 5 and interleukin 4 produced by Peyer's patch T cells selectively enhance immunoglobulin A expression. J Immunol (1987) 2.19
Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol (1981) 2.11
Colonization factors of enterotoxigenic Escherichia coli isolated from children with diarrhea in Argentina. J Clin Microbiol (1991) 2.06
Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med (1988) 2.04
Characterization of new hydrophobic pili of human enterotoxigenic Escherichia coli: a possible new colonization factor. Infect Immun (1984) 1.95
Risk of diarrhea during the first year of life associated with initial and subsequent colonization by specific enteropathogens. Am J Epidemiol (1990) 1.95
Presence of colonization factor antigens on fresh isolates of fecal Escherichia coli: a prospective study. J Infect Dis (1985) 1.87
Immunoglobulin class switching: molecular and cellular analysis. Annu Rev Immunol (1990) 1.81
Development of oral vaccines against enterotoxinogenic Escherichia coli diarrhoea. Vaccine (1989) 1.73
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis (1996) 1.68
Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection. Infect Immun (1995) 1.62
The detection of enteropathogens in acute diarrhea in a family cohort population in rural Egypt. Am J Trop Med Hyg (1986) 1.40
Arousal of mucosal secretory immunoglobulin A antitoxin in rats immunized with Escherichia coli heat-labile enterotoxin. Infect Immun (1982) 1.36
Vaccines for preventing enterotoxigenic Escherichia coli infections in farm animals. Vaccine (1993) 1.35
Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli. J Infect Dis (1998) 1.34
Lack of person-to-person transmission of enterotoxigenic Escherichia coli despite close contact. Am J Epidemiol (1980) 1.34
Vaccination of cows with a K99 extract to protect newborn calves against experimental enterotoxic colibacillosis. Infect Immun (1980) 1.33
Colonization factors of diarrheagenic E. coli and their intestinal receptors. J Ind Microbiol (1995) 1.32
Reactogenicity, immunogenicity and efficacy studies of Escherichia coli type 1 somatic pili parenteral vaccine in man. Scand J Infect Dis Suppl (1982) 1.26
Murine intranasal challenge model for the study of Campylobacter pathogenesis and immunity. Infect Immun (1996) 1.24
Neutralizing antibody responses elicited in mice immunized with recombinant bacillus Calmette-Guérin producing the Schistosoma mansoni glutathione S-transferase. J Immunol (1996) 1.13
Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine. Infect Immun (2000) 1.05
Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide). Vaccine (1993) 1.01
Efficacy of enteric-coated protease in preventing attachment of enterotoxigenic Escherichia coli and diarrheal disease in the RITARD model. Infect Immun (1991) 1.01
Differences in susceptibility of inbred and outbred infant mice to enterotoxigenic Escherichia coli of bovine, porcine and human origin. J Med Microbiol (1990) 0.98
Roles of different putative colonization factor antigens in colonization of human enterotoxigenic Escherichia coli in rabbits. Microb Pathog (1992) 0.96
Etiology and epidemiology of travelers' diarrhea in Asia. Rev Infect Dis (1986) 0.94
Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit. Vaccine (1998) 0.93
Strategies for mucosal vaccine development. Am J Trop Med Hyg (1999) 0.90
Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect Immun (1999) 0.89
Protective antigens against enterotoxigenic Escherichia coli O101:K99,F41 in the infant mouse diarrhea model. Infect Immun (1988) 0.88
Susceptibility of Chinese Meishan and European large white pigs to enterotoxigenic Escherichia coli strains bearing colonization factor K88, 987P, K99, or F41. Am J Vet Res (1991) 0.85
Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen. Infect Immun (1999) 0.82
Adjuvant effects of dimethyl dioctadecyl ammonium bromide, complete Freund's adjuvant and aluminium hydroxide on neutralizing antibody, antibody-isotype and delayed-type hypersensitivity responses to Semliki Forest virus in mice. FEMS Microbiol Immunol (1991) 0.81
Immunoglobulin G subclass responses in mice immunized with plasmid DNA encoding the CFA/I fimbria of enterotoxigenic Escherichia coli. Immunol Lett (1998) 0.78
Therapy of suspected septicemia in neonatal foals using plasma-containing antibodies to core lipopolysaccharide (LPS). J Vet Intern Med (1989) 0.78
Evolutionary and functional relationships of colonization factor antigen i and other class 5 adhesive fimbriae of enterotoxigenic Escherichia coli. Infect Immun (2004) 1.68
Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation. Exp Hematol (2010) 1.56
Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun (2002) 1.34
Wound trauma increases radiation-induced mortality by activation of iNOS pathway and elevation of cytokine concentrations and bacterial infection. Radiat Res (2010) 1.33
Embedded weapons-grade tungsten alloy shrapnel rapidly induces metastatic high-grade rhabdomyosarcomas in F344 rats. Environ Health Perspect (2005) 1.32
Genistein protects against biomarkers of delayed lung sequelae in mice surviving high-dose total body irradiation. J Radiat Res (2008) 1.29
Delta-tocotrienol protects mouse and human hematopoietic progenitors from gamma-irradiation through extracellular signal-regulated kinase/mammalian target of rapamycin signaling. Haematologica (2010) 1.03
Development of a murine model of chronic rhinosinusitis. Otolaryngol Head Neck Surg (2006) 1.02
Subcutaneous administration of genistein prior to lethal irradiation supports multilineage, hematopoietic progenitor cell recovery and survival. Int J Radiat Biol (2007) 0.96
Mucosal and systemic immune responses in patients with diarrhea due to CS6-expressing enterotoxigenic Escherichia coli. Infect Immun (2007) 0.95
Recruitment of murine neutrophils in vivo through endogenous sialidase activity. J Biol Chem (2002) 0.93
Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine (2003) 0.91
Tocopherol succinate: modulation of antioxidant enzymes and oncogene expression, and hematopoietic recovery. Int J Radiat Oncol Biol Phys (2010) 0.90
Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G. Clin Vaccine Immunol (2008) 0.90
Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. Am J Transplant (2002) 0.87
Protective effect of a polyherbal preparation, Brahma rasayana against tumor growth and lung metastasis in rat prostate model system. J Exp Ther Oncol (2004) 0.87
The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine. Vaccine (2005) 0.85
Identification and characterization of hydrophobic Escherichia coli virulence proteins by liquid chromatography-electrospray ionization mass spectrometry. Anal Biochem (2002) 0.83
Intranasal immunization of BALB/c mice with enterotoxigenic Escherichia coli colonization factor CS6 encapsulated in biodegradable poly(DL-lactide-co-glycolide) microspheres. Vaccine (2005) 0.82
Murine antibody response to intranasally administered enterotoxigenic Escherichia coli colonization factor CS6. Vaccine (2003) 0.81
Can homeopathic treatment slow prostate cancer growth? Integr Cancer Ther (2006) 0.81
Mucosal immunization of BALB/c mice using enterotoxigenic Escherichia coli colonization factors CFA/I and CS6 administered with and without a mutant heat-labile enterotoxin. Vaccine (2003) 0.81
Microencapsulated subunit vaccine approach to enterotoxigenic Escherichia coli and other mucosal pathogens. Adv Drug Deliv Rev (2005) 0.80
Susceptibility of irradiated B6D2F1/J mice to Klebsiella pneumoniae administered intratracheally: a pulmonary infection model in an immunocompromised host. Comp Med (2003) 0.78
Long-term systemic and mucosal antibody responses measured in BALB/c mice following intranasal challenge with viable enterotoxigenic Escherichia coli. FEMS Immunol Med Microbiol (2006) 0.78
The encapsulation of enterotoxigenic Escherichia coli colonization factor CS3 in biodegradable microspheres enhances the murine antibody response following intranasal administration. Microbiology (2006) 0.75